CING
Cingulate Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.10
−2.30%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- -$0.51
- Revenue estimate
- $540.0K
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.45
- EPS estimate
- -$0.63
- Revenue actual
- —
- Revenue estimate
- $166.7K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 9
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -38.2%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $27
- PT range
- $9.00 – $44
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026